Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Anti-CTLA-4 Monoclonal Antibody AGEN1884

Known as: AGEN-1884, AGEN1884 
A recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune… Expand
National Institutes of Health

Related topics

Related topics

2 relations
CTLA4 protein, humanantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution
BackgroundAngiosarcoma is an uncommon endothelial malignancy and a highly aggressive soft tissue sarcoma. Due to its infiltrative… Expand
Is this relevant?
2018
2018
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody
CTLA-4 and CD28 exemplify a co-inhibitory and co-stimulatory signaling axis that dynamically sculpts the interaction of antigen… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2018
2018
Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.
3075Background: AGEN1884 is a novel fully human IgG1 monoclonal antibody targeting cytotoxic T lymphocyte-associated protein 4… Expand
Is this relevant?
2018
2018
Phase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors.
 
Is this relevant?
Review
2018
Review
2018
Evaluation of Peripheral T-Cell Subset Proliferation as a Pharmacodynamic Assay to Guide the Development of Anti-CTLA-4 and PD-1 Antibody Combinations in Patients With Solid Tumors
• Antigen-speci c T-cell activation is regulated by a balance of co-stimulatory and co-inhibitory signals, such as those mediated… Expand
Is this relevant?
2018
2018
Phase I, open-label ascending dose trial of anti-CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti-PD-1/PD-L1 therapy.
 
Is this relevant?
2017
2017
Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies.
3075Background: AGEN1884 is a fully human IgG1 monoclonal antibody targeting the co-inhibitory protein cytotoxic T lymphocyte… Expand
Is this relevant?
2017
2017
Abstract 3654: AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model
Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) play important non-redundant… Expand
Is this relevant?
2016
2016
Abstract 5005: AGEN1884 and AGEN2041: Two functionally distinct anti-CTLA-4 antagonist antibodies
CTLA-4 is an important negative regulator of T cell function. Together with CD28, these two co-receptors exemplify a co… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE